Agendia

Agendia is a company that specializes in precision oncology, which is the use of molecular diagnostics to guide personalized treatment decisions for cancer patients. Agendia was founded in 2003 as a spin-off from the Netherlands Cancer Institute and is headquartered in Irvine, California, with a European office in Amsterdam, Netherlands. Agenus Inc reported revenue of $57.9M for FY 2022.

Agendia's main product is MammaPrint, a 70-gene signature test that predicts the risk of recurrence and the benefit of chemotherapy for early-stage breast cancer patients. MammaPrint is the only test of its kind that has been validated by prospective randomized trials and is endorsed by international guidelines. Agendia also offers BluePrint, an 80-gene molecular subtyping test that identifies the functional subtype of breast cancer and helps to select the optimal targeted therapy.

Agendia is also involved in several research projects and collaborations to develop new tests and solutions for other types of cancer, such as colorectal, lung, prostate, and ovarian cancer. Agendia has received several awards and recognitions for its innovation and excellence, such as the Frost & Sullivan European Oncology Diagnostics Product Leadership Award in 2019 and the MedTech Breakthrough Award for Best Personalized Medicine Innovation in 2020.

Agendia's mission is to improve the quality of life and outcomes of cancer patients by providing them with actionable information that empowers them and their physicians to make the best treatment choices. Agendia believes that precision oncology is the future of cancer care and is committed to advancing the field with its cutting-edge technology and expertise.

Foundation: 2003
Headquarters: Amsterdam, Netherlands
Website: https://agendia.com/